SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Exterior of Novo Nordisk's location in Mainz, Germany
Supply chain
Novo’s Ozempic to Remain in Shortage Into Q4 as Supply Woes Continue
Novo Nordisk’s continuing supply problems for semaglutide come as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures.
September 3, 2024
 · 
2 min read
 · 
Tristan Manalac
Healthcare worker administers a vaccine to a patient
COVID-19
Novavax Catches Up to Competitors With FDA Approval for Updated COVID-19 Boosters
Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a recombinant version of the virus’ spike protein to elicit protection.
September 3, 2024
 · 
2 min read
 · 
Tristan Manalac
A human eye and human ear
Editorial
Eyes, Ears Get Their Due With Cell and Gene Therapy
With promising early results, cell and gene therapies are making headway against both rare and common ocular and auditory diseases.
September 3, 2024
 · 
4 min read
 · 
Heather McKenzie
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Travere, Avadel and Roche
The FDA has three regulatory milestones in the next two weeks, including a decision on a subcutaneous formulation of an effective multiple sclerosis therapy.
September 3, 2024
 · 
3 min read
 · 
Tristan Manalac
An eye and DNA
Gene Therapy
Beyond Rare Disease: Wet AMD Gene Therapy Could Reach Millions
With gene therapies by REGENXBIO and AbbVie, Adverum and others in mid- or late-stage trials, this therapeutic class could soon be an option for this common cause of blindness in the elderly.
September 3, 2024
 · 
7 min read
 · 
Kate Goodwin
FDA Sign in front of FDA Buildings
FDA
The FDA Needs a Dedicated ‘Center for Rare Diseases’
The agency’s inertia and bureaucratic roadblocks are throttling hope for millions of patients. A new center of excellence would provide a solution.
September 3, 2024
 · 
6 min read
 · 
Henry I. Miller
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Clinical research
NuCana Shares Plummet as Another Chemotherapy Replacement Fails Phase II
NuCana’s chemotherapy replacement has failed to improve progression-free survival in a Phase II test, sending the biotech’s shares down by 50%.
August 30, 2024
 · 
1 min read
 · 
Annalee Armstrong
Pictured: Alnylam headquarters in Massachusetts/iS
Rare diseases
Alnylam Builds ATTR-CM Case for Vutrisiran With Strong Phase III Survival Data
Despite the added survival benefit for its drug, Alnylam still faces steep competition from Pfizer, whose ATTR-CM therapies have become established treatment options.
August 30, 2024
 · 
2 min read
 · 
Tristan Manalac
U.S. Capitol surrounded by money and pill bottles/Taylor Tieden for BioSpace
Editorial
With Lilly’s Zepbound Price Cut and Novo’s Impending Senate Hearing, Wegovy Is in the Hot Seat
Eli Lilly this week announced plans to sell single-dose vials of its weight loss drug Zepbound directly to consumers. Novo Nordisk could adopt a similar strategy for Wegovy as its CEO is set to testify Sept. 24 before the Senate health committee.
August 30, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS